Annals of Surgical Oncology

• 

  Publication Venue For

  • Patterns and Impact of Fragmented Care in Stage II and III Gastric Cancer. 2022
  • Oncologic Outcomes of Multi-Institutional Minimally Invasive Inguinal Lymph Node Dissection for Melanoma Compared with Open Inguinal Dissection in the Second Multicenter Selective Lymphadenectomy Trial (MSLT-II). 2022
  • ASO Visual Abstract: Racial Disparities in Surgery for Malignant Bowel Obstruction..  29:3134-3135. 2022
  • Circulating Tumor Cells and Breast Cancer: The Long and Winding Road Behind and Before Us..  29:2747-2749. 2022
  • Diversity Among Surgical Faculty, Residents, and Oncology Fellows from 2011/2012 to 2019/2020..  29:2763-2765. 2022
  • Racial Disparities in Surgery for Malignant Bowel Obstruction..  29:3122-3133. 2022
  • ASO Visual Abstract: Epigenetic Signatures Predict Pathologic Nodal Stage in Breast Cancer Patients with Estrogen-Receptor-Positive, Clinically Node-Positive Disease. 2022
  • ASO Author Reflections: Entering the Era of Biomarker-Driven Management of the Axilla. 2022
  • Epigenetic Signatures Predict Pathologic Nodal Stage in Breast Cancer Patients with Estrogen Receptor-Positive, Clinically Node-Positive Disease. 2022
  • Predicting Genomic Alterations of Phosphatidylinositol-3 Kinase Signaling in Hepatocellular Carcinoma: A Radiogenomics Study Based on Next-Generation Sequencing and Contrast-Enhanced CT. 2022
  • ASO Author Reflections: Decision Support Tools Are Needed to Address Dissatisfaction Among Women Seeking Post-Mastectomy Breast Reconstruction..  29:1120-1121. 2022
  • ASO Author Reflections: Identifying Modifiable and Non-Modifiable Risk Factors of Readmission and Short-Term Mortality in Chondrosarcoma..  29:1409-1410. 2022
  • ASO Visual Abstract: Identifying Modifiable and Non-Modifiable Risk Factors of Readmission and Short-Term Mortality in Chondrosarcoma: A National Cancer Database Study..  29:1411-1412. 2022
  • Dissatisfaction After Post-Mastectomy Breast Reconstruction: A Mixed-Methods Study..  29:1109-1119. 2022
  • Identifying Modifiable and Non-modifiable Risk Factors of Readmission and Short-Term Mortality in Chondrosarcoma: A National Cancer Database Study..  29:1392-1408. 2022
  • ASO Visual Abstract: Contralateral Axillary Nodal Metastases-Stage IV Disease or a Manifestation of Progressive Locally Advanced Breast Cancer?.  28:608-609. 2021
  • ASO Visual Abstract: Dissatisfaction After Post-Mastectomy Breast Reconstruction: A Mixed-Methods Study..  28:720-721. 2021
  • ASO Visual Abstract: Identifying Modifiable and Non-Modifiable Risk Factors of Readmission and Short-Term Mortality in Osteosarcoma-A National Cancer Database Study..  28:449-450. 2021
  • ASO Visual Abstract: Limited Reporting of Histopathologic Details in a Multi-Institutional Academic Cohort of Phyllodes Tumors: Time for Standardization..  28:465-466. 2021
  • ASO Visual Abstract: Mortality in Older Patients with Breast Cancer Undergoing Breast Surgery-How Low is "Low Risk"?.  28:645. 2021
  • ASO Visual Abstract: Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients..  28:524. 2021
  • Correction to: Dissatisfaction After Post-Mastectomy Breast Reconstruction: A Mixed-Methods Study..  28:898. 2021
  • Correction to: The Devil's in the Details: Discrepancy Between Biopsy Thickness and Final Pathology in Acral Melanoma..  28:876. 2021
  • Identifying Modifiable and Non-modifiable Risk Factors of Readmission and Short-Term Mortality in Osteosarcoma: A National Cancer Database Study..  28:7961-7972. 2021
  • Limited Reporting of Histopathologic Details in a Multi-Institutional Academic Cohort of Phyllodes Tumors: Time for Standardization..  28:7404-7409. 2021
  • Predictors of False Negative Sentinel Lymph Node Biopsy in Clinically Localized Merkel Cell Carcinoma..  28:6995-7003. 2021
  • Staging and Surveillance of Myxoid Liposarcoma: Follow-up Assessment and the Metastatic Pattern of 169 Patients Suggests Inadequacy of Current Practice Standards..  28:7903-7911. 2021
  • ASO Author Reflections: Gene Expression-Profiling and Implications for Adjuvant Therapy in Melanoma..  28:3511. 2021
  • Adjuvant Radiation Therapy for Clinical Stage III Melanoma in the Modern Therapeutic Era..  28:3512-3521. 2021
  • Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma..  28:3501-3510. 2021
  • Nodal Recurrence as Primary Driver of Early Relapse in Patients with SLN-Positive Melanoma: What Does It Mean for Providers and Patients?.  28:3452-3454. 2021
  • "Going Flat" After Mastectomy: Patient-Reported Outcomes by Online Survey..  28:2493-2505. 2021
  • ASO Author Reflections: Moving the Ball Forward Toward De-Escalation of Axillary Surgery for Patients with Clinically Node-Positive Disease..  28:2619-2620. 2021
  • ASO Visual Abstract: "Going Flat" After Mastectomy: Patient-Reported Outcomes by Online Survey..  28:2507. 2021
  • Assessing the Burden of Nodal Disease for Breast Cancer Patients with Clinically Positive Nodes: Hope for More Limited Axillary Surgery..  28:2609-2618. 2021
  • Morbidity and Mortality of Total Pelvic Exenteration for Malignancy in the US..  28:2790-2800. 2021
  • The Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In Situ in Patients with Intraductal Papilloma without Atypia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 034)..  28:2573-2578. 2021
  • Treatment Patterns and Outcomes of Women with Breast Cancer and Supraclavicular Nodal Metastases..  28:2146-2154. 2021
  • Detailed Analysis of Margin Positivity and the Site of Local Recurrence After Pancreaticoduodenectomy..  28:539-549. 2021
  • Impact of Postoperative Chemotherapy on the Survival of Patients with High-Grade Gastroenteropancreatic Neuroendocrine Carcinoma..  28:114-120. 2021
  • ASO Author Reflection: Postoperative Chemotherapy for Nonmetastatic, Poorly Differentiated Gastroenteropancreatic Neuroendocrine Carcinomas..  27:804-805. 2020
  • ASO Author Reflections: Adjuvant Therapy is Effective for Melanoma Patients with Positive Sentinel Lymph Node Biopsy Who Forgo Completion Lymphadenectomy..  27:5126-5127. 2020
  • ASO Author Reflections: Implementation of a New Hepatic Artery Infusion Program for Colorectal Liver Metastases is Safe, Feasible, and Effective..  27:5096-5097. 2020
  • ASO Author Reflections: What is the Most Appropriate Surgical Management for Men with Breast Cancer?.  27:697-698. 2020
  • Adjuvant Therapy is Effective for Melanoma Patients with a Positive Sentinel Lymph Node Biopsy Who Forego Completion Lymphadenectomy..  27:5121-5125. 2020
  • Implementation of a Hepatic Artery Infusion Program: Initial Patient Selection and Perioperative Outcomes of Concurrent Hepatic Artery Infusion and Systemic Chemotherapy for Colorectal Liver Metastases..  27:5086-5095. 2020
  • Melanomas of Unknown Primary May Have a Distinct Molecular Classification to Explain Differences in Patient Outcomes..  27:4870-4871. 2020
  • Oncologic Outcomes After Isolated Limb Infusion for Advanced Melanoma: An International Comparison of the Procedure and Outcomes Between the United States and Australia..  27:5107-5118. 2020
  • Short-Term Risk of Performing Concurrent Procedures with Hepatic Artery Infusion Pump Placement..  27:5098-5106. 2020
  • National Trends in Immediate Breast Reconstruction: An Analysis of Implant-Based Versus Autologous Reconstruction After Mastectomy..  27:4777-4785. 2020
  • Surgery for Men with Breast Cancer: Do the Same Data Still Apply?.  27:4720-4729. 2020
  • Breast Cancer Surgery Decision Role Perceptions and Choice of Surgery..  27:3623-3632. 2020
  • Acral Melanomas of the Sole May Have Worse Prognosis Compared with Other Sites of Acral Melanoma..  27:3121-3122. 2020
  • "Choosing Wisely" in Breast Cancer Surgery: Drivers of Low Value Care..  27:2577-2579. 2020
  • Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and Change..  27:2600-2613. 2020
  • Designing a Rational Follow-Up Schedule for Patients with Extremity Soft Tissue Sarcoma..  27:2033-2041. 2020
  • The Chicago Consensus on Peritoneal Surface Malignancies: Management of Appendiceal Neoplasms..  27:1753-1760. 2020
  • The Chicago Consensus on Peritoneal Surface Malignancies: Management of Colorectal Metastases..  27:1761-1767. 2020
  • The Chicago Consensus on Peritoneal Surface Malignancies: Management of Desmoplastic Small Round Cell Tumor, Breast, and Gastrointestinal Stromal Tumors..  27:1793-1797. 2020
  • The Chicago Consensus on Peritoneal Surface Malignancies: Management of Gastric Metastases..  27:1768-1773. 2020
  • The Chicago Consensus on Peritoneal Surface Malignancies: Management of Neuroendocrine Tumors..  27:1788-1792. 2020
  • The Chicago Consensus on Peritoneal Surface Malignancies: Management of Ovarian Neoplasms..  27:1780-1787. 2020
  • The Chicago Consensus on Peritoneal Surface Malignancies: Management of Peritoneal Mesothelioma..  27:1774-1779. 2020
  • The Chicago Consensus on Peritoneal Surface Malignancies: Palliative Care Considerations..  27:1798-1804. 2020
  • The Chicago Consensus on Peritoneal Surface Malignancies: Standards..  27:1743-1752. 2020
  • International Multicenter Experience of Isolated Limb Infusion for In-Transit Melanoma Metastases in Octogenarian and Nonagenarian Patients..  27:1420-1429. 2020
  • Prediction of Recurrence Patterns from Hepatic Parenchymal Disease After Resection of Colorectal Liver Metastases..  27:188-195. 2020
  • The Landmark Series: Regional Therapy of Recurrent Cutaneous Melanoma..  27:35-42. 2020
  • ASO Author Reflections: The Pressing Need for Germline Genetic Testing..  26:612-613. 2019
  • Correction to: Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis..  26:893. 2019
  • Does Breast Density Increase the Risk of Re-excision for Women with Breast Cancer Having Breast-Conservation Therapy?.  26:4246-4253. 2019
  • Characteristics Associated with Pathologic Nodal Burden in Patients Presenting with Clinical Melanoma Nodal Metastasis..  26:3962-3971. 2019
  • Maintenance of Certification and Continuing Medical Education: Are They Still Required?.  26:3820-3823. 2019
  • Was Reexcision Less Frequent for Patients with Lobular Breast Cancer After Publication of the SSO-ASTRO Margin Guidelines?.  26:3856-3862. 2019
  • Clinicopathological Features of Triple-Negative Breast Cancer Epigenetic Subtypes..  26:3344-3353. 2019
  • Outcomes of Lymph Node Dissection for Non-metastatic Pancreatic Neuroendocrine Tumors: A Propensity Score-Weighted Analysis of the National Cancer Database..  26:2722-2729. 2019
  • A Nomogram for Predicting Cancer-Specific Survival of TNM 8th Edition Stage I Non-small-cell Lung Cancer..  26:2053-2062. 2019
  • Germline Genetic Testing: What the Breast Surgeon Needs to Know..  26:2184-2190. 2019
  • Peripheral Circulating Tumor DNA Detection Predicts Poor Outcomes After Liver Resection for Metastatic Colorectal Cancer..  26:1824-1832. 2019
  • ASO Author Reflections: Progression after Resection of Noninvasive or Microinvasive Intraductal Papillary Mucinous Neoplasms..  25:822-823. 2018
  • Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution Series..  25:3527-3534. 2018
  • The Association of Extent of Axillary Surgery and Survival in Women with N2-3 Invasive Breast Cancer..  25:3019-3029. 2018
  • The Changing Paradigms for Breast Cancer Surgery: Performing Fewer and Less-Invasive Operations..  25:2807-2812. 2018
  • Metaplastic Breast Cancer Treatment and Outcomes in 2500 Patients: A Retrospective Analysis of a National Oncology Database..  25:2249-2260. 2018
  • Progression Patterns in the Remnant Pancreas after Resection of Non-Invasive or Micro-Invasive Intraductal Papillary Mucinous Neoplasms (IPMN)..  25:1752-1759. 2018
  • SPECT/CT: Looking Beyond Sentinel Lymph Node Identification for Improving Patient Outcomes..  25:1467-1468. 2018
  • Impact of Micro- and Macroscopically Positive Surgical Margins on Survival after Resection of Adrenocortical Carcinoma..  25:1425-1431. 2018
  • Reasons Associated with Total Thyroidectomy as Initial Surgical Management of an Indeterminate Thyroid Nodule..  25:1410-1417. 2018
  • Association of Delivery System Integration and Outcomes for Major Cancer Surgery..  25:856-863. 2018
  • Survival Prediction in Pancreatic Ductal Adenocarcinoma by Quantitative Computed Tomography Image Analysis..  25:1034-1042. 2018
  • How Low Can We Go-and Should We? Risk Reduction for Minimal-Volume DCIS..  25:354-355. 2018
  • The Impact of Primary Tumor Location on Long-Term Survival in Patients Undergoing Hepatic Resection for Metastatic Colon Cancer..  25:431-438. 2018
  • Long-Term Survival after Complete Surgical Resection and Adjuvant Immunotherapy for Distant Melanoma Metastases..  24:3991-4000. 2017
  • Treatment Patterns and Outcomes for Patients with Adrenocortical Carcinoma Associated with Hospital Case Volume in the United States: A Reply..  24:618. 2017
  • Association Between Patient Satisfaction and Short-Term Outcomes After Major Cancer Surgery..  24:3486-3493. 2017
  • Patient Age and Tumor Subtype Predict the Extent of Axillary Surgery Among Breast Cancer Patients Eligible for the American College of Surgeons Oncology Group Trial Z0011..  24:3559-3566. 2017
  • Surgical Upstaging Rates for Vacuum Assisted Biopsy Proven DCIS: Implications for Active Surveillance Trials..  24:3534-3540. 2017
  • Utility of Serum Inflammatory Markers for Predicting Microvascular Invasion and Survival for Patients with Hepatocellular Carcinoma..  24:3706-3714. 2017
  • Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer..  24:3116-3123. 2017
  • Computed Tomography Image Texture: A Noninvasive Prognostic Marker of Hepatic Recurrence After Hepatectomy for Metastatic Colorectal Cancer..  24:2482-2490. 2017
  • Sentinel Lymph Node Biopsy for Recurrent Melanoma: A Multicenter Study..  24:2728-2733. 2017
  • Tumor-Associated Macrophage Infiltration in Colorectal Cancer Liver Metastases is Associated With Better Outcome..  24:1835-1842. 2017
  • Anticipatory Positive Urine Tests for Bladder Cancer..  24:1747-1753. 2017
  • Actual 10-Year Survivors After Resection of Hepatocellular Carcinoma..  24:1358-1366. 2017
  • Percutaneous Peritoneal Lavage for the Rapid Staging of Gastric and Pancreatic Cancer..  24:1174-1179. 2017
  • Clinical Utility of the 12-Gene DCIS Score Assay: Impact on Radiotherapy Recommendations for Patients with Ductal Carcinoma In Situ..  24:660-668. 2017
  • Postmastectomy Radiotherapy: An American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Focused Guideline Update..  24:38-51. 2017
  • Surgical Strategy and Outcomes in Duodenal Gastrointestinal Stromal Tumor..  24:202-210. 2017
  • Active Surveillance for DCIS: The Importance of Selection Criteria and Monitoring..  23:4134-4136. 2016
  • Clinicopathological Features and Prognosis of Mixed-Type T1a Gastric Cancer Based on Lauren's Classification..  23:784-791. 2016
  • Society of Surgical Oncology-American Society for Radiation Oncology-American Society of Clinical Oncology Consensus Guideline on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Ductal Carcinoma In Situ..  23:3801-3810. 2016
  • Early Adoption of the SSO-ASTRO Consensus Guidelines on Margins for Breast-Conserving Surgery with Whole-Breast Irradiation in Stage I and II Invasive Breast Cancer: Initial Experience from Memorial Sloan Kettering Cancer Center..  23:3239-3246. 2016
  • Factors Associated with Recurrence Rates and Long-Term Survival in Women Diagnosed with Breast Cancer Ages 40 and Younger..  23:3212-3220. 2016
  • Neoadjuvant Systemic Therapy for Breast Cancer: Factors Influencing Surgeons' Referrals..  23:3510-3517. 2016
  • Should New "No Ink On Tumor" Lumpectomy Margin Guidelines be Applied to Ductal Carcinoma In Situ (DCIS)? A Retrospective Review Using Shaved Cavity Margins..  23:3453-3458. 2016
  • The Impact of the Affordable Care Act on North Carolinian Breast Cancer Patients Seeking Financial Support for Treatment..  23:3412-3417. 2016
  • The Use of Re-irradiation in Locally Recurrent, Non-metastatic Rectal Cancer..  23:3609-3615. 2016
  • Critical Assessment of Clinical Prognostic Tools in Melanoma..  23:2753-2761. 2016
  • Health-Related Quality of Life After Pancreatectomy: Results From a Randomized Controlled Trial..  23:2137-2145. 2016
  • Computed Tomography-Based Limb Volume Measurements for Isolated Limb Infusion in Melanoma..  23:1090-1095. 2016
  • Observation versus Resection for Small Asymptomatic Pancreatic Neuroendocrine Tumors: A Matched Case-Control Study..  23:1361-1370. 2016
  • Incidence of Adjacent Synchronous Invasive Carcinoma and/or Ductal Carcinoma In-situ in Patients with Lobular Neoplasia on Core Biopsy: Results from a Prospective Multi-Institutional Registry (TBCRC 020)..  23:722-728. 2016
  • Role of Adjuvant Radiotherapy in Locally Advanced Colonic Carcinoma in the Modern Chemotherapy Era..  23:856-862. 2016
  • Patients Treated at Low-Volume Centers have Higher Rates of Incomplete Resection and Compromised Outcomes: Analysis of 31,129 Patients with Papillary Thyroid Cancer..  23:403-409. 2016
  • Adrenal Imaging Features Predict Malignancy Better than Tumor Size..  22 Suppl 3:S721-S727. 2015
  • Evaluation of Adjuvant Radiation Therapy for Resected Gallbladder Carcinoma: A Multi-institutional Experience..  22 Suppl 3:S1100-S1106. 2015
  • Evaluation of Pathologic Nipple Discharge: What is the Added Diagnostic Value of MRI?.  22 Suppl 3:S435-S441. 2015
  • Percutaneous Preoperative Biliary Drainage for Resectable Perihilar Cholangiocarcinoma: No Association with Survival and No Increase in Seeding Metastases..  22 Suppl 3:S1156-S1163. 2015
  • FOLFIRINOX Induction Therapy for Stage 3 Pancreatic Adenocarcinoma..  22:3512-3521. 2015
  • [(99m)Tc]Tilmanocept Accurately Detects Sentinel Lymph Nodes and Predicts Node Pathology Status in Patients with Oral Squamous Cell Carcinoma of the Head and Neck: Results of a Phase III Multi-institutional Trial..  22:3708-3715. 2015
  • Positive postoperative CEA is a strong predictor of recurrence for patients after resection for colorectal liver metastases..  22:3087-3093. 2015
  • The use of radiation therapy in localized high-grade soft tissue sarcoma and potential impact on survival..  22:2831-2838. 2015
  • Recurrence After Partial Hepatectomy for Metastatic Colorectal Cancer: Potentially Curative Role of Salvage Repeat Resection..  22:2761-2771. 2015
  • Quality of life after isolated limb infusion for in-transit melanoma of the extremity..  22:1694-1700. 2015
  • Clinical features and outcome of primary pancreatic lymphoma..  22:1176-1184. 2015
  • Benefit of adjuvant chemotherapy after resection of stage II (T1-2N1M0) non-small cell lung cancer in elderly patients..  22:642-648. 2015
  • Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin D in melanoma..  22:482-488. 2015
  • In-transit melanoma metastases: incidence, prognosis, and the role of lymphadenectomy..  22:358-360. 2015
  • Surgical patterns of care in patients with invasive breast cancer treated with neoadjuvant systemic therapy and breast magnetic resonance imaging: results of a secondary analysis of TBCRC 017..  22:75-81. 2015
  • A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases..  21:4278-4283. 2014
  • Readmission after pancreatic resection: causes and causality pattern..  21:4342-4350. 2014
  • Predictors of hemodynamic instability during surgery for pheochromocytoma..  21:3865-3871. 2014
  • Robotic thyroidectomy for cancer in the US: patterns of use and short-term outcomes..  21:3859-3864. 2014
  • Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States..  21:3515-3521. 2014
  • Treatment patterns and outcomes for patients with adrenocortical carcinoma associated with hospital case volume in the United States..  21:3509-3514. 2014
  • Immunotherapy following regional chemotherapy treatment of advanced extremity melanoma..  21:2525-2531. 2014
  • Regional chemotherapy for unresectable intrahepatic cholangiocarcinoma: a potential role for dynamic magnetic resonance imaging as an imaging biomarker and a survival update from two prospective clinical trials..  21:2675-2683. 2014
  • Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States..  21:1501-1505. 2014
  • Hypoxia in melanoma: using optical spectroscopy and EF5 to assess tumor oxygenation before and during regional chemotherapy for melanoma..  21:1435-1440. 2014
  • Prognostic significance of the highest peripancreatic lymph node in biliary tract adenocarcinoma..  21:979-985. 2014
  • SRC family kinase inhibition as a novel strategy to augment melphalan-based regional chemotherapy of advanced extremity melanoma..  21:1024-1030. 2014
  • Society of Surgical Oncology-American Society for Radiation Oncology consensus guideline on margins for breast-conserving surgery with whole-breast irradiation in stages I and II invasive breast cancer..  21:704-716. 2014
  • Treatment of extensive metastatic colorectal cancer to the liver with systemic and hepatic arterial infusion chemotherapy and two-stage hepatic resection: the role of salvage therapy for recurrent disease..  21:815-821. 2014
  • Floxuridine hepatic arterial infusion associated biliary toxicity is increased by concurrent administration of systemic bevacizumab..  21:479-486. 2014
  • Resection of residual disease after isolated limb infusion (ILI) is equivalent to a complete response after ILI-alone in advanced extremity melanoma..  21:650-655. 2014
  • Comparison between perioperative and postoperative chemotherapy after potentially curative hepatic resection for metastatic colorectal cancer..  20:4312-4321. 2013
  • Predicting dysplasia and invasive carcinoma in intraductal papillary mucinous neoplasms of the pancreas: development of a preoperative nomogram..  20:4348-4355. 2013
  • The cost-effectiveness of neoadjuvant chemoradiation is superior to a surgery-first approach in the treatment of pancreatic head adenocarcinoma..  20 Suppl 3:S500-S508. 2013
  • Prediction of disease-free survival in hepatocellular carcinoma by gene expression profiling..  20:3747-3753. 2013
  • Resident education in the era of patient safety: a nationwide analysis of outcomes and complications in resident-assisted oncologic surgery..  20:3715-3724. 2013
  • Incidentally discovered pancreatic intraepithelial neoplasia: what is its clinical significance?.  20:3643-3647. 2013
  • Outcome and prognostic factors after adrenalectomy for patients with distant adrenal metastasis..  20:3491-3496. 2013
  • Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort..  20:3254-3258. 2013
  • Conversion to complete resection and/or ablation using hepatic artery infusional chemotherapy in patients with unresectable liver metastases from colorectal cancer: a decade of experience at a single institution..  20:2901-2907. 2013
  • Perioperative complications influence recurrence and survival after resection of hepatic colorectal metastases..  20:2477-2484. 2013
  • Assessment of advanced gastric cancer management in the United States..  20:2124-2131. 2013
  • Frequency and intensity of postoperative surveillance after curative treatment of pancreatic cancer: a cost-effectiveness analysis..  20:2197-2203. 2013
  • Risk of occult irresectable disease at liver resection for hepatic colorectal cancer metastases: a contemporary analysis..  20:2029-2034. 2013
  • Plasma cytokine analysis in patients with advanced extremity melanoma undergoing isolated limb infusion..  20:1128-1135. 2013
  • Malignant progression in IPMN: a cohort analysis of patients initially selected for resection or observation..  20:440-447. 2013
  • Treatment trends and predictors of adjuvant and neoadjuvant therapy for gastric adenocarcinoma in the United States..  20:362-370. 2013
  • BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer..  20:47-52. 2013
  • Detailed pathologic characteristics of the primary colorectal tumor independently predict outcome after hepatectomy for metastases..  20:148-154. 2013
  • Hepatic pedicle clamping during hepatic resection for colorectal liver metastases: no impact on survival or hepatic recurrence..  20:285-294. 2013
  • Management and recurrence patterns of desmoids tumors: a multi-institutional analysis of 211 patients..  19:4036-4042. 2012
  • Synchronous resection of primary and liver metastases for neuroendocrine tumors..  19:4270-4277. 2012
  • The impact of vascular resection on early postoperative outcomes after pancreaticoduodenectomy: an analysis of the American College of Surgeons National Surgical Quality Improvement Program database..  19:4068-4077. 2012
  • A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity..  19:3896-3905. 2012
  • Tumor proximity to the recurrent laryngeal nerve in patients with primary hyperparathyroidism undergoing parathyroidectomy..  19:3823-3826. 2012
  • Outcomes after total skin-sparing mastectomy and immediate reconstruction in 657 breasts..  19:3402-3409. 2012
  • Presentation and management of gastrointestinal stromal tumors of the duodenum: a multi-institutional analysis..  19:3351-3360. 2012
  • Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline..  19:3313-3324. 2012
  • Impact of obesity and body fat distribution on survival after pancreaticoduodenectomy for pancreatic adenocarcinoma..  19:2908-2916. 2012
  • Pathologic response to preoperative chemotherapy in colorectal liver metastases: fibrosis, not necrosis, predicts outcome..  19:2797-2804. 2012
  • Patterns of recurrence following complete response to regional chemotherapy for in-transit melanoma..  19:2563-2571. 2012
  • Racial and gender disparities and the role of primary tumor type on inpatient outcomes following craniotomy for brain metastases..  19:2657-2663. 2012
  • Resection of adrenocortical carcinoma liver metastasis: is it justified?.  19:2643-2651. 2012
  • Simultaneous medullary and differentiated thyroid cancer: a population-level analysis of an increasingly common entity..  19:2635-2642. 2012
  • A pathway-based approach to identify molecular biomarkers in cancer..  19 Suppl 3:S620-S624. 2012
  • CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases..  19 Suppl 3:S339-S346. 2012
  • Putatively functional PLCE1 variants and susceptibility to esophageal squamous cell carcinoma (ESCC): a case-control study in eastern Chinese populations..  19:2403-2410. 2012
  • Aggressive variants of papillary thyroid cancer: incidence, characteristics and predictors of survival among 43,738 patients..  19:1874-1880. 2012
  • Ex vivo evaluation of preoperatively treated rectal cancer specimens of patients undergoing radical resection..  19:1954-1958. 2012
  • A multi-institutional experience of repeat regional chemotherapy for recurrent melanoma of extremities..  19:1637-1643. 2012
  • A population-based comparison of adenocarcinoma of the large and small intestine: insights into a rare disease..  19:1439-1445. 2012
  • Biliary sclerosis after hepatic arterial infusion pump chemotherapy for patients with colorectal cancer liver metastasis: incidence, clinical features, and risk factors..  19:1609-1617. 2012
  • Carcinoma of the ampulla of Vater: patterns of failure following resection and benefit of chemoradiotherapy..  19:1535-1540. 2012
  • Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease..  19:1663-1669. 2012
  • Adjuvant radiotherapy in the treatment of invasive intraductal papillary mucinous neoplasm of the pancreas: an analysis of the surveillance, epidemiology, and end results registry..  19:1316-1323. 2012
  • Patterns of recurrence after ablation of colorectal cancer liver metastases..  19:834-841. 2012
  • Is port site resection necessary in the surgical management of gallbladder cancer?.  19:409-417. 2012
  • Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades..  19:169-175. 2012
  • Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer..  18:3566-3571. 2011
  • Features associated with successful recruitment of diverse patients onto cancer clinical trials: report from the American College of Surgeons Oncology Group..  18:3544-3550. 2011
  • Significance of pathologic response to preoperative therapy in pancreatic cancer: the future ain't what it used to be..  18:3533-3534. 2011
  • Selective organ preservation in operable locally advanced head and neck squamous cell carcinomas guided by primary site restaging biopsy: long-term results of two sequential brown university oncology group chemoradiotherapy studies..  18:3479-3485. 2011
  • Adrenalectomy in older Americans has increased morbidity and mortality: an analysis of 6,416 patients..  18:2714-2721. 2011
  • Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response..  18:2192-2199. 2011
  • Standardizing regional therapy: developing a consensus on optimal utilization of regional chemotherapy treatments in melanoma..  18:1814-1818. 2011
  • Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial..  18:1319-1326. 2011
  • Prospective evaluation of laparoscopic celiac plexus block in patients with unresectable pancreatic adenocarcinoma..  18:636-641. 2011
  • Pancreatic cyst fluid and serum mucin levels predict dysplasia in intraductal papillary mucinous neoplasms of the pancreas..  18:199-206. 2011
  • Adjuvant radiation therapy for distal pancreatic cancer: is there a role?.  17:3082-3084. 2010
  • Biobanking of human pancreas cancer tissue: impact of ex-vivo procurement times on RNA quality..  17:2229-2236. 2010
  • Inhibition of poly(ADP-ribose) polymerase enhances the effect of chemotherapy in an animal model of regional therapy for the treatment of advanced extremity malignant melanoma..  17:2247-2254. 2010
  • Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation..  17:1794-1801. 2010
  • Proton-beam, intensity-modulated, and/or intraoperative electron radiation therapy combined with aggressive anterior surgical resection for retroperitoneal sarcomas..  17:1515-1529. 2010
  • The adrenal mass: correlation of histopathology with imaging..  17:846-852. 2010
  • Prognostic impact of RT-PCR-based detection of peritoneal micrometastases in patients with pancreatic cancer undergoing curative resection..  16:3333-3339. 2009
  • Defining surgical indications for type I gastric carcinoid tumor..  16:3154-3160. 2009
  • Predictive factors of regional toxicity and serum creatine phosphokinase levels after isolated limb infusion for melanoma: a multi-institutional analysis..  16:2570-2578. 2009
  • Synchronous colorectal liver metastases: is it time to reconsider traditional paradigms of management?.  16:2395-2410. 2009
  • Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases..  16:1844-1851. 2009
  • Timing of multimodality therapy for resectable synchronous colorectal liver metastases: a retrospective multi-institutional analysis..  16:1809-1819. 2009
  • Laparoscopic versus open subtotal gastrectomy for adenocarcinoma: a case-control study..  16:1507-1513. 2009
  • Optimizing regional therapy for melanoma..  16:1095-1097. 2009
  • Optimizing melphalan pharmacokinetics in regional melanoma therapy: does correcting for ideal body weight alter regional response or toxicity?.  16:953-961. 2009
  • Polymorphisms of p16, p27, p73, and MDM2 modulate response and survival of pancreatic cancer patients treated with preoperative chemoradiation..  16:431-439. 2009
  • Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma..  15:3512-3520. 2008
  • Impact of time duration after neoadjuvant therapy to surgery on response and outcome in rectal cancer patients..  15:2636-2638. 2008
  • Isolated limb infusion for in-transit malignant melanoma of the extremity: a well-tolerated but less effective alternative to hyperthermic isolated limb perfusion..  15:2195-2205. 2008
  • Development of an integrated biospecimen bank and multidisciplinary clinical database for pancreatic cancer..  15:1356-1366. 2008
  • A phase II prospective multi-institutional trial of adjuvant active specific immunotherapy following curative resection of colorectal cancer hepatic metastases: cancer and leukemia group B study 89903..  15:158-164. 2008
  • Simultaneous resections of colorectal cancer and synchronous liver metastases: a multi-institutional analysis..  14:3481-3491. 2007
  • Utility of a prognostic nomogram designed for gastric cancer in predicting outcome of patients with R0 resected duodenal adenocarcinoma..  14:3159-3167. 2007
  • Implications of HER2-targeted therapy on extent of surgery for early-stage breast cancer..  22:1404-1405. 2015
  • Cost implications of the SSO-ASTRO consensus guideline on margins for breast-conserving surgery with whole breast irradiation in stage I and II invasive breast cancer..  21:1512-1514. 2014
  • When a chance to cut is not a chance to cure: a future for palliative surgery?.  18:3235-3239. 2011
  • Survival Outcomes Among Patients with Metastatic Breast Cancer: Review of 47,000 Patients. 2021
  • Contralateral Axillary Nodal Metastases: Stage IV Disease or a Manifestation of Progressive Locally Advanced Breast Cancer? 2021
  • Mortality in Older Patients with Breast Cancer Undergoing Breast Surgery: How Low is "Low Risk"? 2021
  • The Devil's in the Details: Discrepancy Between Biopsy Thickness and Final Pathology in Acral Melanoma. 2020
  • Germline Genetic Mutations in a Multi-center Contemporary Cohort of 550 Phyllodes Tumors: An Opportunity for Expanded Multi-gene Panel Testing. 2020
  • Is There a Role for Surgery in Patients with Neuroendocrine Tumors of the Esophagus? A Contemporary View from the NCDB. 2020
  • Efficacy of Talimogene Laherparepvec (T-VEC) Therapy in Patients with In-Transit Melanoma Metastasis Decreases with Increasing Lesion Size. 2019
  • DCIS with Microinvasion: Is It In Situ or Invasive Disease? 2019
  • Neoadjuvant Endocrine Therapy Versus Neoadjuvant Chemotherapy in Node-Positive Invasive Lobular Carcinoma. 2019
  • Perspectives on the Costs of Cancer Care: A Survey of the American Society of Breast Surgeons. 2019
  • Long-Term Oncologic Outcomes After Isolated Limb Infusion for Locoregionally Metastatic Melanoma: An International Multicenter Analysis. 2019
  • Axillary Nodal Evaluation in Elderly Breast Cancer Patients: Potential Effects on Treatment Decisions and Survival. 2018
  • Minimally Invasive Pancreaticoduodenectomy Does Not Improve Use or Time to Initiation of Adjuvant Chemotherapy for Patients With Pancreatic Adenocarcinoma. 2016
  • A national snapshot of satisfaction with breast cancer procedures. 2015
  • A multicenter phase I dose escalation trial to evaluate safety and tolerability of intra-arterial temozolomide for patients with advanced extremity melanoma using normothermic isolated limb infusion. 2015
  • Defining the learning curve for team-based laparoscopic pancreaticoduodenectomy. 2014
  • Surgical treatment of resectable and borderline resectable pancreatic cancer: expert consensus statement by Evans et al. 2009
  • Long-term survival after multidisciplinary management of resected pancreatic adenocarcinoma. 2009